Zinc8 Energy Solutions

NEONMIND BIOSCIENCES (OTCMKTS: NMDBF) STOCK QUOTE

Last Trade: US$0.05 -0.0074 -13.21
Volume: 601
5-Day Change: -1.00%
YTD Change: -1.00%
Market Cap: US$5.840M

LATEST NEWS FROM NEONMIND BIOSCIENCES

Partnered with SRx Health Solutions and BioScript Solutions to Build Out a Network of NeonMind-branded Specialty Mental Health Clinics Across Canada NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF ) ( FRA:6UF ) (" NeonMind '' or the " Company "), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders,... Read More
NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) (" NeonMind '' or the " Company "), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced today it has released preclinical data demonstrating the efficacy of psilocybin in reducing weight gain in obese subjects. In previous preclinical... Read More
NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF ) ( FRA:6UF ) (" NeonMind '' or the " Company "), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced today it has filed a new patent application with the United States Patent and Trademark Office related to a novel mechanism of weight loss... Read More
Completed concrete milestones in its strategy to become a leading psychedelic drug developer and specialty clinics operator. Developed clear drug development pathway for NEO-001, the industry's first psilocybin-based obesity treatment with near-term clinical milestones. Partnered with well-established specialty treatment providers, SRx Health Solutions and BioScript Solutions to build out a network of NeonMind-branded... Read More
NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF ) ( FRA:6UF ) (" NeonMind '' or the " Company "), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced today a strategic partnership with BioScript Solutions, a Canadian leader in specialty care. Under the terms of the partnership, NeonMind and... Read More
NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF )( FRA:6UF ) (" NeonMind '' or the " Company "), an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced today the appointment of Dr. Dinesh Bhayana, MD, CCFP (EM), as the Site Medical Director of its recently announced inaugural specialty clinic... Read More
Mississauga facility expected to begin treatment services in the Second Half of 2022 First location selected as part of a nationwide buildout of NeonMind-branded clinics offering interventional psychiatry treatments NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF ) ( FRA:6UF ) (" NeonMind '' or the " Company "), an integrated drug development and wellness company focused on bringing innovative psychedelic-based... Read More
Dr. Bainbridge's Expertise and Network Provides Safety Best-Practices for Administration of Intravenous Ketamine (IV-Ketamine) at NeonMind Clinics NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF ) ( FRA:6UF ) (" NeonMind '' or the " Company "), an integrated drug development and wellness company, announced today the appointment of Dr. Daniel Bainbridge, MD, FRCPC, past President of the Canadian Anesthesiologists... Read More
NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF ) ( FRA:6UF ) (" NeonMind '' or the " Company "), an integrated drug development and wellness company, announced today that Robert Tessarolo, President and Chief Executive Officer, will participate in the H.C. Wainwright Bioconnect Conference, being held virtually on January 10-13, 2022. H.C. Wainwright Bioconnect Conference Details: Date: January 10-13, 2022 Registration:... Read More
NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF ) ( FRA:6UF ) (" NeonMind '' or the " Company "), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that Robert Tessarolo, President and Chief Executive Officer, will participate in the H.C. Wainwright 2 nd Annual Psychedelics Conference, being... Read More
FDA feedback provides clear clinical path for NEO-001, the first obesity drug therapy focused on neuropharmacological and behavioral changes for sustainable weight loss Company plans to file an IND application for a Phase 1/2 clinical study anticipated to start in H1'2022 NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF ) ( FRA:6UF ) (" NeonMind '' or the " Company "), an integrated drug development and wellness company... Read More
NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF ) ( FRA:6UF ) (" NeonMind '' or the " Company "), an integrated drug development and wellness company, is pleased to announce that President and CEO, Rob Tessarolo, is scheduled to participate in a panel discussion at Lift & Co. Expo's new Psychedelics Business Summit, on November 19, 2021, in Toronto. The panel entitled, "Business Leaders: Committing to Business... Read More
NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF ) ( FRA:6UF ) (" NeonMind '' or the " Company "), an integrated drug development and wellness company, today announced a strategic alliance with SRx Health Solutions (" SRx "), a leading Canadian specialty healthcare services and medical treatment provider, to establish and operate a network of NeonMind-branded specialty clinics to deliver evidence-backed innovative... Read More
Announces Participation in Microdose's Wonderland: Miami on November 8-9, 2021 NeonMind Biosciences Inc. ( CSE:NEON ) ( OTCQB:NMDBF ) ( FRA:6UF ) (" NeonMind "), an integrated drug development and wellness company, today announced that NeonMind was ranked third in Psychedelia Magazine's "8 Industry Innovators'' segment within the magazine's inaugural Winter 2022 issue. NeonMind was recognized for its dual approach in... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS